Advertisement

Topics

Dong-A PharmTech Co. Ltd. Company Profile

16:41 EDT 22nd September 2017 | BioPortfolio


News Articles [38 Associated News Articles listed on BioPortfolio]

Many possible maximum lifespan trajectories

arising fromX.Dong, B.Milholland & J.VijgNature538, 257–259 (2016); doi:10.1038/nature19793The recent Letter by Dong et al. analysed demographic trends to claim that there is a biological limit to m...

CF PharmTech raises $65m to accelerate development of its inhalation products and manufacturing capacity

CF PharmTech announced that it has raised $65M in a Series D financing. Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited (SDIC Fund Management...

Questionable evidence for a limit to human lifespan

arising fromX.Dong, B.Milholland & J.VijgNature538, 257–259 (2016); doi:10.1038/nature19793In their Letter, Dong et al. stated that their results strongly suggested that the maximum lifespan of huma...

Contesting the evidence for limited human lifespan

arising fromX.Dong, B.Milholland & J.Vijg538, 257–259 (2016); doi:10.1038/nature19793In their Letter, Dong et al. claimed that longitudinal mortality data indicate that human lifespan has a limit of...

EU Clears Ineos Takeover of Dong Assets

The European Commission has greenlighted the acquisition of Dong Energy’s oil and gas production by Switzerland-based Ineos. The more than $1 billion purchase includes ten gas and oilfields oper...

Maximum human lifespan may increase to 125 years

arising fromX.Dong, B.Milholland & J.VijgNature538, 257–259 (2016); doi:10.1038/nature19793In their Letter, Dong et al. argue that there is a limit to human lifespan of around 115 years, with

Is there evidence for a limit to human lifespan?

arising fromX.Dong, B.Milholland & J.VijgNature538, 257–259 (2016); doi:10.1038/nature19793In their Letter, Dong et al. claimed to have found evidence for a natural limit to human longevity, based o...

CF PharmTech raises $65M in series D

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds

- Investigational Device : TheraFill® (Atelocollagen Dermal Filler) - Title : A Randomized, Multicenter, Prospective and Paired Comparison of the Efficacy and Safety of TheraFi...

Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES

This trial was performed to evaluate the safety of G-CSF based stem cell therapy and to compare outcome of intracoronary infusion of mobilized PBSCs between patients with AMI and OMI.

The Efficacy and Safety Study of Acupuncture for Polycystic Ovarian Syndrome

This study evaluates the efficacy and safety in improving ovarian function of polycystic ovarian syndrome in adults. Half of patients will receive Dong's extra-point acupuncture therapy, w...

Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA(2) Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP

Typhoid fever remains common, serious, and difficult-to-treat throughout the world including Vietnam. Limitations of the three licensed typhoid vaccines have prevented their use for routi...

Companies [9 Associated Companies listed on BioPortfolio]

Dong-A PharmTech Co. Ltd., Valenta Pharmaceuticals

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

Dong-A PharmTech Co. Ltd.

PharmTech, Inc.

PharmTech, Inc. is a consulting firm providing GMP compliance and validation services to manufacturers in FDA regulated industries. Our consultants provide valuable insight and experience-based knowle...

Dong-A America Corporation

A company's performance is publicly measured by the balance statement but that is not enough. This homepage was made to help you understand the current status of Dong-A Pharmaceutical and what we are ...

Sinobiopharma, Inc.

Sinobiopharma Inc. is a fully integrated and highly innovative specialty pharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in ...

More Information about "Dong-A PharmTech Co. Ltd." on BioPortfolio

We have published hundreds of Dong-A PharmTech Co. Ltd. news stories on BioPortfolio along with dozens of Dong-A PharmTech Co. Ltd. Clinical Trials and PubMed Articles about Dong-A PharmTech Co. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dong-A PharmTech Co. Ltd. Companies in our database. You can also find out about relevant Dong-A PharmTech Co. Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record